Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation
Whereas DAAs rapidly cleared intrahepatic HCV in both groups, immune activation was slower to diminish in PWH. Residual immune activation in PWH warrants further exploration. Clinical Trials Registration. NCT02938013.
Authors
- P. Balasubramaniam (ORCID: https://orcid.org/0000-0001-9673-5949)
- Julia Leep-Lazar
- Ruy M. Ribeiro (ORCID: https://orcid.org/0000-0002-3988-8241)
- Ashwin Balagopal (ORCID: https://orcid.org/0000-0002-6143-3104)
- Mark Sulkowski (ORCID: https://orcid.org/0000-0002-2145-6352)
- Kenneth Bowden (ORCID: https://orcid.org/0000-0002-7529-1127)
- Jeffrey Quinn (ORCID: https://orcid.org/0000-0002-4734-5108)
- Jaiprasath Sachithanandham
- Kathleen Ward (ORCID: https://orcid.org/0000-0003-4552-2585)
Institutions
- Bloomberg (United States) (US)
- Los Alamos National Laboratory (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Johns Hopkins University Applied Physics Laboratory (US)
- Temple University (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1093/infdis/jiae598
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.37